Symbio is thrilled to announce and share the recent press release from Jasper Therapeutics. We are incredibly proud to have been the CRO partner for this successful study. This achievement marks a significant milestone in our collaboration and commitment to advancing innovative therapies for the treatment of Urticaria and other mast cell-mediated diseases. Read full press release, “Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria”.
January 13, 2025, New York, NY and Munster, Germany: Symbio, the global specialist therapeutic clinical research organization, is pleased to announce two key leadership appointments.
Shanna Smith is appointed Chief Commercial Officer. Shanna has a 16-year tenure with Symbio and brings an extensive background in crafting customer solutions in both clinical operations and commercial functions. She has played a pivotal role in driving Symbio’s growth and commitment to quality, building outstanding relationships with clients and investigators, and expanding Symbio’s global presence.
Patrick Ronan is appointed to the Board of Directors of Symbio. Patrick currently serves as an Operating Partner at ARCHIMED, a global investment firm focused on the healthcare industries. He is the former CEO of two life sciences firms, Validant (now Eliquent Life Sciences) and Greenleaf Health, which he founded in 2007. Prior to this, Patrick served as VP Regulatory Policy & External Affairs at Novartis and before that as Chief of Staff at the U.S. Food and Drug Administration (FDA), an executive role where he led the Agency on strategic, operational, and regulatory policy matters.
In a joint statement, Alan Morgan, Chief Executive, and Nick Thornton, Chairman said, “The high caliber of these appointments reflects Symbio’s commitment to bringing the highest levels of expertise to our clients’ development programs. We congratulate Shanna and Patrick and wish them much success and enjoyment in their new roles.”
Press queries contact:
Rose Panico, Symbio Director of Global Marketing
Office: +1-631-474-8531
Mobile: +1-516-994-6683
rose.panico@symbioresearch.com
symbioresearch.com
Symbio is a global specialist therapeutic CRO with exceptional expertise in Dermatology, Aesthetics, Wound Care, Ophthalmology, Inflammation, and Gastroenterology. The business operates across the USA and Europe, with additional expertise in Latin America, and Asia.
Nearly a year ago we informed you about the merger of the Symbio & Dow Group with Proinnovera GmbH.
After successfully going through the integration process, the Group will now finalize this process by renaming the Group from Symbio Proinnovera to Symbio, with a new logo to show the achievement and unity of the Group, not only internally, but also to our customers, vendors
and friends.
This change of name has no effect on the existing relationship with you, legally and organizationally, all stays as it is. There is no change to our Dow Development Laboratory branding or presentation.
Our email addresses will migrate to firstname.lastname@symbioresearch.com over the next few days, but the old address will work for several months.
We will continue to be a Global CRO, dedicated to our clients and fully focused on providing the results they rely on and expect. Please feel to reach out if you have any questions regarding our new look.
Sincerely,
Alan Morgan, Chief Executive Officer, Alan.Morgan@symbioresearch.com
As always, the AAD Annual Meeting was a resounding success. The Symbio team was able to meet with many clients and colleagues to discuss innovations in dermatology. It was great to see you all and we hope to connect again soon. Check out our photos and videos below.
You are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
You are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
It was good to connect with you at The EADV Congress in Berlin. We look forward to seeing you again soon and sharing ideas.
Several members of our Symbio staff had the pleasure of attending this year’s AAD conference in New Orleans. It was an amazing opportunity to connect with our clients in person and meet the companies and individuals responsible for driving innovation in dermatology.
We would like to express our gratitude to all of those who came to visit us, both at our booth and at our festive night at the House of Blues. We can’t wait to return to AAD next year in San Diego, and we are anxious to see all of our colleagues again!
Check out our photos and video below!
You are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationSymbio and Dow Development Laboratories exhibited at EADV Congress 2022 in Milan in September. We met many amazing people and connected with both old friends and new. See you in 2023 in Seville!
Symbio and Dow Development Laboratories exhibited at the 2022 AAD Annual Meeting from March 25 to March 29 at the Boston Convention & Exhibition Center in Boston, MA. The event was a huge success for all. It was wonderful to see so many familiar faces and to make new connections.
View videos of AAD Annual Meeting at the Symbio Booth and our 20th Anniversary Dinner Celebration at SPIN.
You are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
You are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
You are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
You need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More Information
